Patents by Inventor Kai S. Lipinski

Kai S. Lipinski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9057079
    Abstract: The invention relates to improved genetic elements providing high levels of expression of operably-linked genes in a variety of tissues. In particular, fragments of unmethylated, CpG islands of less than 2 kb are shown to provide enhanced transgene expression and have advantages in terms of vector construction and cloning capacity.
    Type: Grant
    Filed: February 2, 2004
    Date of Patent: June 16, 2015
    Assignee: EMD Millipore Corporation
    Inventors: Steven G. Williams, Robert L. Crombie, Kai S. Lipinski, Alistair S. Irvine
  • Publication number: 20080222742
    Abstract: The invention relates to improved genetic elements providing high levels of expression of operably-linked genes in a variety of tissues. In particular, fragments of unmethylated, CpG islands of less than 2 kb are shown to provide enhanced transgene expression and have advantages in terms of vector construction and cloning capacity.
    Type: Application
    Filed: February 2, 2004
    Publication date: September 11, 2008
    Inventors: Steven G. Williams, Robert L. Crombie, Kai S. Lipinski, Alistair S. Irvine
  • Patent number: 7179646
    Abstract: Disclosed are DNA elements and constructs useful for obtaining tumor-selective gene expression in tumors having a mutated ?-catenin/APC pathway. In particular, the use of these constructs to express genes encoding therapeutic proteins in colorectal cancer cells is described. The constructs comprise multiple repeats of a TCF-binding element operably linked to a promoter. By means of such a construct, tumor cell-specific expression of a prodrug-converting enzyme such as nitroreductase may be achieved. Coupled with systemic administration of a suitable prodrug, such as CB1954, selective killing of such tumor cells can be demonstrated.
    Type: Grant
    Filed: June 26, 2003
    Date of Patent: February 20, 2007
    Assignee: Innovata PLC
    Inventors: Lawrence S. Young, Kai S. Lipinski, Christopher J. Wrighton
  • Publication number: 20040048293
    Abstract: Disclosed are DNA elements and constructs useful for obtaining tumour-selective gene expression in tumours having a mutated &bgr;-catenin/APC pathway. In particular, the use of these constructs to express genes encoding therapeutic proteins in colorectal cancer cells is described. The constructs comprise multiple repeats of a TCF-binding element operably linked to a promoter. By means of such a construct, tumour cell-specific expression of a prodrug-converting enzyme such as nitroreductase may be achieved. Coupled with systemic administration of a suitable prodrug, such as CB1954, selective killing of such tumour cells can be demonstrated.
    Type: Application
    Filed: June 26, 2003
    Publication date: March 11, 2004
    Inventors: Lawrence S. Young, Kai S. Lipinski, Christopher J. Wrighton
  • Patent number: 6608037
    Abstract: Disclosed are DNA elements and constructs useful for obtaining tumour-selective gene expression in tumours having a mutated &bgr;-catenin/APC pathway. In particular, the use of these constructs to express genes encoding therapeutic proteins in colorectal cancer cells is described. The constructs comprise multiple repeats of a TCF-binding element operably linked to a promoter. By means of such a construct, tumour cell-specific expression of a prodrug-converting enzyme such as nitroreductase may be achieved. Coupled with systemic administration of a suitable prodrug, such as CB1954, selective killing of such tumour cells can be demonstrated.
    Type: Grant
    Filed: March 2, 2001
    Date of Patent: August 19, 2003
    Assignee: M.L. Laboratories PLC
    Inventors: Lawrence S. Young, Kai S. Lipinski, Christopher J. Wrighton
  • Publication number: 20020165173
    Abstract: Disclosed are DNA elements and constructs useful for obtaining tumour-selective gene expression in tumours having a mutated &bgr;-catenin/APC pathway. In particular, the use of these constructs to express genes encoding therapeutic proteins in colorectal cancer cells is described. The constructs comprise multiple repeats of a TCF-binding element operably linked to a promoter. By means of such a construct, tumour cell-specific expression of a prodrug-converting enzyme such as nitroreductase may be achieved. Coupled with systemic administration of a suitable prodrug, such as CB1954, selective killing of such tumour cells can be demonstrated.
    Type: Application
    Filed: March 2, 2001
    Publication date: November 7, 2002
    Applicant: Cobra Therapeutics Limited
    Inventors: Lawrence S. Young, Kai S. Lipinski, Christopher J. Wrighton